Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
79 studies found for:    "Langerhans cell histiocytosis"
Show Display Options
Rank Status Study
21 Completed Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy
Conditions: Accelerated Phase Chronic Myelogenous Leukemia;   Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome;   Acute Undifferentiated Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Grade III Lymphomatoid Granulomatosis;   Adult Langerhans Cell Histiocytosis;   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Aggressive NK-cell Leukemia;   AIDS-related Diffuse Large Cell Lymphoma;   AIDS-related Diffuse Mixed Cell Lymphoma;   AIDS-related Diffuse Small Cleaved Cell Lymphoma;   AIDS-related Immunoblastic Large Cell Lymphoma;   AIDS-related Lymphoblastic Lymphoma;   AIDS-related Malignancies;   AIDS-related Small Noncleaved Cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative;   Chronic Eosinophilic Leukemia;   Chronic Myelomonocytic Leukemia;   Chronic Neutrophilic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia;   Clear Cell Renal Cell Carcinoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   de Novo Myelodysplastic Syndromes;   Essential Thrombocythemia;   Extramedullary Plasmacytoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   HIV Infection;   HIV-associated Hodgkin Lymphoma;   Intraocular Lymphoma;   Isolated Plasmacytoma of Bone;   Light Chain Deposition Disease;   Mast Cell Leukemia;   Myelodysplastic Syndrome With Isolated Del(5q);   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Myeloid/NK-cell Acute Leukemia;   Nodal Marginal Zone B-cell Lymphoma;   Noncutaneous Extranodal Lymphoma;   Osteolytic Lesions of Multiple Myeloma;   Peripheral T-cell Lymphoma;   Plasma Cell Neoplasm;   Polycythemia Vera;   Post-transplant Lymphoproliferative Disorder;   Previously Treated Myelodysplastic Syndromes;   Primary Myelofibrosis;   Primary Systemic Amyloidosis;   Progressive Hairy Cell Leukemia, Initial Treatment;   Prolymphocytic Leukemia;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Renal Cell Cancer;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Refractory Multiple Myeloma;   Relapsing Chronic Myelogenous Leukemia;   Stage IV Renal Cell Cancer;   T-cell Large Granular Lymphocyte Leukemia;   Testicular Lymphoma;   Unspecified Adult Solid Tumor, Protocol Specific;   Waldenström Macroglobulinemia
Interventions: Drug: sunitinib malate;   Other: pharmacological study;   Other: laboratory biomarker analysis
22 Unknown  H-9926-LCH III: Treatment Protocol of the Third International Study for Langerhans Cell Histiocytosis
Condition: Leukemia
Interventions: Drug: Prednisone, Vinblastin, 6-mercaptopuroine;   Drug: Leucovorin, Methotrexate, Vinblastine, Prednisone
23 Terminated Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers.
Conditions: Melanoma;   Thyroid Cancer;   Colorectal Cancer;   Non-small Cell Lung Cancer;   Cholangiocarcinoma;   Histiocytosis;   Hairy Cell Leukemia
Intervention: Drug: PLX8394
24 Active, not recruiting Ceftriaxone in Non-neutropenic Fever
Conditions: Histiocytosis;   Pediatric Patients With Cancer
Intervention:
25 Recruiting CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant
Conditions: Leukemia;   Lymphoma;   Bone Marrow Failure;   Immunodeficiencies;   Histiocytosis;   Sickle Cell Disease;   Beta Thalassemia;   Inborn Errors of Metabolism
Interventions: Drug: Full Intensity with TBI;   Drug: Full Intensity;   Drug: Reduced Intensity;   Drug: Reduced Intensity (Fanconi)
26 Recruiting HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies
Conditions: Acute Myeloid Leukemia;   Acute Lymphocytic Leukemia;   Myelodysplasia;   Chronic Myeloid Leukemia;   Histiocytosis
Interventions: Drug: Chemotherapy and antibodies;   Device: Miltenyi Biotec CliniMACS;   Procedure: Allogeneic stem cell transplantation
27 Terminated Unrelated Donor Transplant for Malignant and Non-Malignant Disorders
Conditions: Leukemia;   Lymphoma;   Bone Marrow Failure Syndromes;   Immunodeficiencies;   Histiocytosis
Interventions: Drug: Myeloablative chemotherapy and TBI;   Drug: Myeloablative chemotherapy;   Drug: Reduced Intensity Chemoimmunotherapy;   Drug: Reduced Intensity for Fanconi Anemia
28 Terminated Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies
Conditions: Immunologic Deficiency Syndromes;   Chediak-Higashi Syndrome;   Common Variable Immunodeficiency;   Graft Versus Host Disease;   X-Linked Lymphoproliferative Syndrome;   Familial Erythrophagocytic Lymphohistiocytosis;   Hemophagocytic Lymphohistiocytosis;   X-linked Agammaglobulinemia;   Wiskott-Aldrich Syndrome;   Chronic Granulomatous Disease;   X-linked Hyper IgM Syndrome;   Severe Combined Immunodeficiency;   Leukocyte Adhesion Deficiency Syndrome;   Virus-Associated Hemophagocytic Syndrome
Interventions: Drug: anti-thymocyte globulin;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: etoposide;   Drug: methotrexate;   Drug: methylprednisolone;   Drug: prednisone;   Procedure: Allogeneic Bone Marrow Transplantation
29 Recruiting Dabrafenib and Trametinib in People With BRAF V600E Mutation Positive Lesions in Erdheim Chester Disease
Condition: BRAF V600E Mutation
Interventions: Drug: Dabrafenib Mesylate;   Drug: Trametinib Dimethyl Sulfoxide
30 Unknown  Pilot Study of Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients With Life Threatening Hemophagocytic Disorders
Conditions: Chediak-Higashi Syndrome;   Graft Versus Host Disease;   X-Linked Lymphoproliferative Syndrome;   Familial Erythrophagocytic Lymphohistiocytosis;   Hemophagocytic Lymphohistiocytosis;   Virus-Associated Hemophagocytic Syndrome
Interventions: Drug: anti-thymocyte globulin;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: etoposide;   Drug: filgrastim;   Drug: methotrexate;   Procedure: allogeneic hematopoietic stem cell transplantation
31 Recruiting Clinical and Basic Investigations Into Erdheim Chester Disease
Conditions: Myelofibrosis;   Gaucher Disease;   Pulmonary Fibrosis;   Hermansky-Pudlak Syndrome (HPS);   Cancer
Intervention:
32 Completed Longitudinal Study of Cognition With Niemann-Pick Disease, Type C
Condition: Niemann-Pick Disease, Type C
Intervention:
33 Terminated Safety Study of rhASM Enzyme Replacement Therapy in Adults With Acid Sphingomyelinase Deficiency (Niemann-Pick Disease)
Conditions: Acid Sphingomyelinase Deficiency;   Niemann-Pick Disease
Intervention: Drug: rhASM
34 Recruiting Reduced Intensity Conditioning for Hemophagocytic Syndromes or Selected Primary Immune Deficiencies (BMT CTN 1204)
Conditions: Hemophagocytic Lymphohistiocytosis;   Chronic Active Epstein-Barr Virus Infection;   Chronic Granulomatous Disease;   HIGM-1;   Leukocyte Adhesion Deficiency;   IPEX
Intervention: Biological: Hematopoietic Stem Cell Transplant
35 Completed PET Scan of Brain Metabolism in Relation to Age and Disease
Conditions: Alzheimer's Disease;   Brain Neoplasm;   Niemann Pick Disease
Intervention: Drug: 15 O Water
36 Unknown  Combination Chemotherapy Followed By Donor Stem Cell Transplant in Treating Patients With Hemophagocytic Lymphohistiocytosis
Condition: Nonneoplastic Condition
Interventions: Biological: anti-thymocyte globulin;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: dexamethasone;   Drug: etoposide;   Drug: methotrexate;   Drug: mycophenolate mofetil;   Drug: therapeutic hydrocortisone;   Other: laboratory biomarker analysis;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: biopsy
37 Recruiting Safety Study of Gene Modified Donor T Cell Infusion After Stem Cell Transplant for Non-Malignant Diseases
Conditions: Primary Immune Deficiency Disorders;   Hemophagocytic Lymphohistiocytosis;   Inherited Bone Marrow Failure Syndrome;   Hemoglobinopathies;   Metabolic Disorders
Intervention: Biological: BPX-501 and AP1903
38 Completed Application of Miglustat in Patients With Niemann-Pick Type C
Condition: Niemann-Pick Disease Type C
Intervention: Drug: Miglustat
39 Terminated
Has Results
Hematopoietic Stem Cell Transplantation (HCT) for Inborn Errors of Metabolism
Conditions: Hurler's Syndrome;   Maroteaux-Lamy Syndrome;   Sly Syndrome;   Alpha Mannosidosis;   Fucosidosis;   Aspartylglucosaminuria;   Sphingolipidoses;   Krabbe Disease;   Wolman's Disease;   Niemann-Pick Disease Type B;   Niemann-Pick Disease, Type C
Interventions: Procedure: Stem Cell Transplantation;   Drug: Cyclophosphamide;   Drug: Campath-1H;   Drug: Busulfan
40 Recruiting Evaluation of Biochemical Markers and Clinical Investigation of Niemann-Pick Disease, Type C
Condition: Neimann-Pick Disease, Type C
Intervention:

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years